1. Ahmann DL, Bisel HF, Hahn RG (1974) Phase II clinical trial of isophosphamide (NSC 109724) in patients with advanced breast cancer. Cancer Chemother Rep 58:861–865
2. Ahmann DL, Bisel HF, Hahn RG, Eagen RT, Edmonson JH, Steinfeld JL, Tormey DC, Taylor WF (1975) An analysis of multiple drug programs in the treatment of patients with advanced breast cancer utilizing 5-fluorouracil, cyclophosphamide and prednisone with or without vincristine. Cancer 36:1925–1935
3. Ahmann DL, Bisel HF, Eagan RT, Edmonson JH, Hahn RG, O’Connell MJ, Frytak S (1976) Phase II evaluation of VP16-213 (NSC 141540) and cytembena (NSC 104801) in patients with advanced breast cancer. Cancer Treat Rep 60:633–635
4. Ahmann DL, O’Connell MJ, Bisel HF, Edmonson JH, Hahn RG, Frytak S (1977) Phase II study of dianhydrogalactical and ICRF 159 in patients with advanced breast cancer previously exposed to cytotoxic chemotherapy. Cancer Treat Rep 61:81–87
5. Ahmann DL, O’Connell MJ, Hahn RG, Bisel HF, Lee RA, Edmonson JH (1977) An evaluation of early or deleayed adjuvant chemotherapy in premenopausal patients with advanced breast cancer undergoing oophorectomy. N Engl J Med 297:356–360